Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.3K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.8K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural and functional benchmarking of monolayer- and bioreactor-generated hiPSC-derived cardiomyocytes.

APL bioengineering·2026
Same author

Design and Manufacturing Principles of Smart Fibers.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer.

JAMA network open·2026
Same author

Mapping and engineering the human cell-cell interactome.

Nature biotechnology·2026
Same author

Hypoxia-mediated epicardial signaling coordinates coronary angiogenesis and myocardial expansion during zebrafish ventricle maturation.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Benchtop Fabrication and Integration of Laser-Induced Graphene Strain Gauges and Stimulation Electrodes in Muscle on a Chip Devices.

Advanced functional materials·2026

Related Experiment Video

Updated: Mar 26, 2026

Nitropeptide Profiling and Identification Illustrated by Angiotensin II
07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

6.2K

Angiotensin II Induced Cardiac Dysfunction on a Chip.

Renita E Horton1,2, Moran Yadid1, Megan L McCain1

  • 1Disease Biophysics Group, Wyss Institute for Biologically Inspired Engineering, John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, United States of America.

Plos One
|January 26, 2016
PubMed
Summary

This study developed a heart-on-a-chip model using angiotensin II (ANG II) to simulate cardiac dysfunction. The model revealed that ANG II causes genetic and functional changes before significant structural remodeling, aiding disease mechanism research.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K
Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

11.3K

Related Experiment Videos

Last Updated: Mar 26, 2026

Nitropeptide Profiling and Identification Illustrated by Angiotensin II
07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

6.2K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

18.5K
Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

11.3K

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Research
  • In Vitro Disease Modeling

Background:

  • Studying systemic diseases in isolation is crucial for understanding dysfunction.
  • Existing models may not fully capture native cardiac tissue complexity.

Purpose of the Study:

  • To develop and validate an in vitro cardiac dysfunction model using angiotensin II (ANG II).
  • To investigate the mechanisms of cardiac dysfunction and assess tissue health.
  • To establish a platform for therapeutic development.

Main Methods:

  • Utilized a heart-on-a-chip platform with muscular thin films (MTF) to mimic cardiac tissue.
  • Exposed cardiac tissues to ANG II to induce pathological responses.
  • Measured gene expression, calcium transients, contractile stress, and morphology.

Main Results:

  • ANG II induced pathological gene expression (e.g., natriuretic peptide B, Rho GTPase 1, T-type calcium channels).
  • Observed increased proarrhythmic events and reduced peak systolic stresses.
  • Demonstrated that genetic and functional impairments precede significant morphological changes.

Conclusions:

  • The developed in vitro model effectively recapitulates ANG II-induced cardiac dysfunction.
  • Pathological genetic profiles and functional impairment occur before structural remodeling.
  • This model serves as a valuable tool for studying cardiac disease mechanisms and testing therapeutics.